<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of IDH-mutant astrocytoma (grades 2, 3, and 4) in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of IDH-mutant astrocytoma (grades 2, 3, and 4) in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial treatment of IDH-mutant astrocytoma (grades 2, 3, and 4) in adults</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_footnotes"><p>IDH: isocitrate dehydrogenase; MRI: magnetic resonance imaging; WHO: World Health Organization; RT: radiation therapy; PCV: procarbazine, lomustine, vincristine.</p>
<p>* Modest amounts of residual grade 2 tumor after surgery, even measuring &gt;1 to 2 cm, may be reasonably observed in some cases, provided that the patient is asymptomatic from the tumor aside from well-controlled epilepsy.</p>
<p>¶ Patients who are uncomfortable with the uncertainties of observation may reasonably choose immediate postoperative therapy, even though this approach is associated with more side effects in the short term. In addition, individual risk factors (eg, age &gt;40 years, preoperative tumor volume ≥4 cm, neurologic deficits) are sometimes used to select patients for immediate further therapy after gross total resection. Practice in this area varies among experts. Refer to UpToDate topic on treatment of IDH-mutant astrocytomas for further details.</p>
Δ Selection is individualized. Both temozolomide regimens are considered appropriate by expert groups for grade 4 IDH-mutant astrocytomas, and comparative evidence in these tumors is not available. There is no evidence to support one regimen as "more aggressive" than another in terms of efficacy, and the risk of hematologic toxicity may be higher with concurrent therapy, particularly in females.</div><div id="graphicVersion">Graphic 135150 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
